Although mesenchymal stem cells (MSCs) have been identified as a potential novel therapeutic strategy for multiple sclerosis (MS), existing evidence regarding the effectiveness and safety of this strategy remains inconclusive.
The rationale for use of adult stem cells as a treatment for neurological diseases such as multiple sclerosis arose from the hope that they had the capacity to foster repair of the CNS through tissue integration and differentiation into neural cells.
Results
of enrolled studies demonstrated that patients with COVID-19 pneumonia who received MSC inoculation showed a decreased mortality compared with counterparts who received conventional treatment
Systemic rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, are chronic autoimmune diseases affecting multiple organs and tissues. Despite recent advances in treatment, patients still experience significant morbidity and disability.
Results showed that stem-cell transplantation is an effective therapy for Parkinson’s disease
and is influenced by cell type used for transplantation, and duration of effectiveness after transplantation.
Stem cell transplantation (SCT) has paved the way for treatment of autoimmune diseases. SCT has been investigated in type 1 diabetes mellitus (T1DM) as an autoimmune-based disorder, but previous studies have not presented a comprehensive view of its effect on treatment of T1DM.
Because of their ease of procurement and differentiation into a variety of connective tissues, MSCs have taken an early lead over other stem cell types and as such are highly represented in ongoing clinical trials for a variety of conditions including diabetes.
This study in Science Direct reviews how different types of stem cells can treat diabetes.
In recent years, mesenchymal stem cells (MSCs)-based therapy has emerged as a promising strategy for the treatment of IBDs due to their potent immuno-modulatory and tissue-repair functions
EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS.
The RHA.org - Your Trusted Guide to Regenerative Health
© 2024 All Rights Reserved.